cyrilzakka/clinical-trials huggingface dataset:
Cancer Prevention in Women With a BRCA Mutation

This study aims to develop a follow-up telephone-based genetic counselling (FTGC) intervention for women with a BRCA1 or BRCA2 mutation who have received genetic counseling in the past. Typically, when women undergo genetic testing, they receive standard genetic counselling prior to testing in order to fully understand the procedure and associated implications. If a woman's genetic test results are positive for a mutation, cancer prevention options are then discussed with a counsellor. However, in Canada, there is currently no formal follow-up counselling for women with a BRCA mutation to provide ongoing guidance and support about latest risk reduction strategies. Standard care relies on women making contact for any follow-up questions or concerns they may have. As a result, these women might not have the most current information regarding genetic risk assessment and prevention options. Therefore, individuals are being asked to participate in this study to aid research about the efficacy of FTGC in women with a BRCA mutation.


Eligibility Criteria:
Inclusion Criteria:

* Confirmed BRCA mutation
* Age 35 to 70 years
* No previous bilateral salpingo-oophorectomy
* No previous or current ovarian cancer
* At least 12 months since genetic testing or most recent contact by Narod follow-up study
* Can speak and understand English

Exclusion Criteria:

* Currently receiving treatment for another cancer diagnosis
* Pregnant
* Given birth in the last 6 months
* Booked surgical date for BSO
Diabetes Discharge Transitional CGM Study (DDT-CGM)

Intervention group will receive brief diabetic education, CGM education and use and have a CGM placed before discharge. They will also sign up for "Cloud" access of their CGM data. A medical assistant will review their CGM data daily to make sure they are using the CGM adequately. The principal investigator will review the CGM data and call the patient for a brief phone evaluation of their glucoses and their transition from the hospital to outpatient care. The will be called 4 times between discharge and day 15 by the principal investigator.

Standard treatment group will receive a blinded CGM to be reviewed 30 days after discharge.

Reduction in hospitalizations and ER visits within the first 30 days is the primary outcome. Time in range, hypoglycemia, hyperglycemia and patient satisfaction will also be evaluated 30 days after discharge.

Patients admitted to a community hospital with diabetes will be evaluated for being high risk for rehospitalization. High risk patients will be identified and those that are found to be high risk will be evaluated for entrance to the study and consented.

Those that consent will be randomized to two arms, an intervention arm and a standard care arm with CGM monitoring.

Intervention will include a brief 15 minute diabetic education session and a 15 minute brief education on how to use the Freestyle Libre CGM. A sensor will be placed and initiated before discharge. They will also sign up for a Freestyle Libre View account and grant access to the intervention team. The will receive a handout of reasons to call the principal investigator during the first 15 days and will be told to access the PI through the hospital operator. The PI will call the patient on day 3-4, day 5-6, day 9-10 and day 14-15 after reviewing their CGM data. The PI will review their glucoses and also any concerns from their hospitalization. The team can then help bridge any treatment or care gaps with the patients PCP or care team. The CGM data will be recorded for the first 14 days and data will be sent to the PCP.

The standard treatment arm will get 15 minutes of education on how to use the Libre Pro blinded CGM sensor and the sensor will be placed before discharge. The sensor will be sent back the the team and downloaded. After 30 days the data will be sent to the patients PCP.

Outcomes will be measured for 30 days from discharge.

Patient satisfaction will be measured by a phone interview in both groups once after 31-40 days from discharge

Eligibility Criteria:
Inclusion Criteria:

Type 2 diabetes plus one additional criteria during hospitalization:

A1C greater than or equal to 9, New diagnosis of diabetes Type 2 and A1C greater than or equal to 8, On insulin, On sulfonylurea, Deemed to by high risk by hospitalist staff for post-hospitalization complications, Acute Heart Failure, Acute Coronary Syndrome (ACS), Stroke, or a TIA.

-

Exclusion Criteria:

Type 1 Diabetes, or Not high risk (as above), or Already using a CGM, or Unable to understand or use a CGM, or Unable or unwilling to use a CGM, or Participating in another clinical trial within 30 days.

-
Evaluation of a Portable Device for Assessing Sleep Disordered Breathing in Congestive Heart Failure

The purpose of this study is to evaluate an approved, portable device for assessing Sleep Disordered Breathing in Congestive Heart Failure.


Eligibility Criteria:
Inclusion Criteria:

* Moderate to severe heart failure (as determined via Echocardiogram or treating physician)

Exclusion Criteria:

* Clinically significant asthma requiring therapy
* Significant (parenchymal) lung disease
* Severe pulmonary hypertension
* Hypercapnia (PCO2 \> 60mmHg)
* Cardiogenic Shock
* Severe chronic renal failure
* Narcotic abuse/intravenous drug use (including heart failure due to alcohol abuse or chemotherapy, HIV+ and Hepatitis C)
* Methicillin- resistant Staphylococcus aureus infection
* Tracheotomy
* Enrolled in any concurrent study that may confound the results of this study
* Nocturnal positive airway pressure or oxygen
* Inability or refusal to sign patient consent form
* Inability or refusal to adhere to protocol requirements
Airway Responsiveness in Patients With AECOPD Mechanical Ventilation by Inspiratory and Bronchial Dilation Testchronic Obstructive Pulmonary Disease

In the patients with COPD mechanical ventilation, the bronchial dilatation is very common. However, the evaluation of the efficacy of the medical examination and other subjective indicators, such as doctors, depends on the doctor's experience; at present, there is no objective evaluation index. For patients with mechanical ventilation, the risk of cross infection can not only increase the risk of cross infection, but also increase the workload of clinical doctors and nurses. Therefore, this study proposes an objective evaluation method to evaluate the response of COPD patients to bronchial dilation. The hypothesis of this study can be used to guide the clinical medication through the test of the bronchus. If the patients with bronchial dilation test positive were used in the test, the patients were not used. In this evaluation method, the changes of airway resistance were measured by the accurate measurement of the patients with inhaled bronchial dilatation.


Eligibility Criteria:
Inclusion Criteria:

* Acute exacerbation of chronic obstructive pulmonary disease
* The mechanical ventilation time of the outdoor endotracheal intubation in the intensive care unit was less than 48 hours

Exclusion Criteria:

* asthma
* has received tracheotomy
* long term mechanical ventilation (which has been accepted for more than 21 days).
* severe pneumonia
* Patients who cannot use a patient with bronchial dilation
* there's a taboo on the use of a sedative.
* refusal to participate in the study
* 48 hours to pull out the tube
Safety Study of Abatacept in Sweden

The primary purpose of this study is to assess incidence rates of targeted infections, malignancies and mortality among patients with rheumatoid arthritis who are treated with abatacept.


Eligibility Criteria:
Inclusion Criteria:

* Resident of Sweden

Exclusion Criteria:

* None
Celebrex Short Versus Long Therapy In Osteoarthritis Of The Knee

This is a phase III, multicentre, randomized, double blind, parallel-group, pilot study designed to compare a long term (12 weeks) versus a short term (2 weeks) treatment with celecoxib 200 mg/die in treatment and prevention of new flare in patients with osteoarthritis of the knee.


Eligibility Criteria:
Inclusion Criteria:

* diagnosis of OA of the knee according to the ACR Classification Criteria for osteoarthritis;
* patients in flare

Exclusion Criteria:

* any concomitant inflammatory rheumatic condition which may interfere with the assessment of OA
* clinical or radiological evidence of chondrocalcinosis
To Improve Depressive Symptoms Using a Web-App

This study is being done to answer a question on whether a Web App-based Lifestyle Physical Activity Promotion Program is effective in improving depressive symptom experience of midlife Korean American women (WPAPP-K).

This study is being done to answer a question on whether a Web App-based Lifestyle Physical Activity Promotion Program is effective in improving depressive symptom experience of midlife Korean American women (WPAPP-K). Korean American midlife women tend to suffer from depressive symptoms due to their menopausal transition, cultural background, age, and gender. The WPAPP-K program that the investigators are testing is designed to help Korean American midlife women by providing information and coaching/support to increase lifestyle physical activity and subsequently improve their depressive symptom experience during the menopausal transition. The research team wants to know if the program improves depressive symptom experience of Korean American midlife women as designed.

Eligibility Criteria:
Inclusion Criteria:

* self-reported midlife Korean-American women
* aged 40 to 60 years
* whose parents and grandparents are of Korean descent;
* who can read and write English or Korean;
* who currently reside in the United States;
* who are sedentary (without any disabilities preventing physical activity);
* who are online through computers or mobile devices;
* have experienced depressive symptoms during the past two weeks (1 to 10 on the Patient Health Questionnaire \[PHQ-9\],which is equivalent to the cut-point of minimal to moderate depression.

Exclusion Criteria:

* major signs or symptoms suggestive of pulmonary or CVD
* history of a myocardial infarction, stroke, or Type I diabetes mellitus
* blood pressure higher than 160/100 mm Hg
* Use of beta-blockers, diltiazem, or verapamil
HRQOL in Locally Advanced Thyroid Carcinoma

The purpose of this study was to explore the changes of health-related quality of life (HRQOL) in patients with locally advanced thyroid cancer (LATC) receiving TKI drugs (anlotinib, lenvatinib, etc.).

Surgical resection is the cornerstone of treatment for thyroid cancer. However, some patients present with locally advanced disease at the time of diagnosis, and they are not eligible for radical resection. Another patients still had the risk of recurrence after surgery, endocrine therapy and iodine-131 treatment. Tyrosine kinase inhibitors (TKI) have been proved to be effective in thyroid cancer patients. However, it was still unclear whether TKI drugs had influence on the HRQOL of LATC patients. The purpose of this study was to explore the changes of health-related quality of life (HRQOL) in patients with locally advanced thyroid cancer (LATC) receiving TKI drugs (anlotinib, lenvatinib, etc.).Participants enroll the study after informed consent, and quality of life will be assessed using quality of life questionnaires EORTC QLQ C30, and EORTC THY 47 before surgery, and 1,3,6 and 12 months after treatment.

Eligibility Criteria:
Inclusion Criteria:

* Patients age (18-70 year old)
* Diagnosis of locally advanced thyroid cancer
* Patient receiving TKI drugs.

Exclusion Criteria:

* pregnancy or breastfeeding women;
* history of other malignant diseases, unstable angina, myocardial infarction, cerebral infarction or cerebral hemorrhage within 6 months; (3) patients missing questionnaires greater than 3 times.
Endometrial Transcript Profile with Progesterone After Post-ovulatory Mifepristone

The goal of this exploratory trial is to determine the endometrial gene expression profile induced by exogenous progesterone after postovulatory administration of mifepristone. It will also learn about the plasticity ofr the endometrial response to progesterone. The main questions it aims to answer are:

Is exogenous progesterone able to modulate the gene expression of endometrial transcripts that have been altered by mifepristone?

Researchers will compare the endometrial gene expression profiles with exogeonous progesterone to a placebo (a look-alike substance that contains no drug) after postovulatory administration of mifepristone.

Participants will:

Do ovulation follow-up tests at home assesing LH in urine Visit the hospital 2 days after a positive LH for mifepristone administration and ultrasonography check of ovaries and uterus.

Starting from the next day, take progesterone or placebo for 3 days. Visit the hospital 2 days after that for ultrasonography check of ovaries and uterus and for an endometrial and blood sample collection.

The endometrial samples will be processed to isolate the RNA and for histological assessment. Gene expression profiles will be determined by RNA-seq.

Objective: To determine the effect of progesterone supplementation on the mid-secretory endometrial transcript profile after postovulatory administration of mifepristone.

Design: A randomized, double-blind, placebo-controlled study. Setting: Tertiary academic medical center Subjects: A total of 9 Hispanic women of proven fertility who had been surgically sterilized.

Interventions: Participating women received a single dose of mifepristone 200mg 48 hours after the LH peak (LH+2, LH+0=LH peak). Endometrial samples were obtained on LH+7 after vaginal administration of micronized progesterone (600mg/day) for 3 days (LH+3 to LH+5). Each woman contributed with one cycle treated with placebo and another with progesterone (group A). Additionally, endometrial samples were obtained on LH+7 from subset of 4 women who did not receive mifepristone; with each one contributing with one cycle treated with vaginal progesterone supplementation or placebo as a reference (group B). Endometrial thickness, circulating progesterone levels, and endometrial histology were also documented in all cycles. RNA-seq was used to identify genes whose transcript levels significantly changed by the administration of progesterone versus placebo, with postovulatory administration of mifepristone. The transcript profiles of these genes were further evaluated in the endometrial samples from group B.

Eligibility Criteria:
Inclusion Criteria:

* proven fertility
* regular menstrual cycles
* surgically sterilized at least one year before participating in the protocol

Exclusion Criteria:

* chronic medical problems
* abnormal results of screening blood tests
* ovarian masses
* symptomatic endometriosis
* uterine leiomyomata
* being under chronic medication or taking hormones or drugs able to modify the metabolism of steroid hormones in the 3 preceding months to study enrollment
Orthopaedic Hand and Upper Extremity Data Repository

The purpose of this research is to investigate multiple facets of non-traumatic and traumatic orthopaedic health issues. Studies under this protocol will investigate a variety of research questions concerning traumatic and non-traumatic health issues in the Orthopaedic Hand and Upper Extremity Service.


Eligibility Criteria:
Inclusion Criteria:

* Over 18 years
* Patients presenting to the Orthopaedic Hand and Upper Extremity Service for traumatic or non-traumatic issues
* English speaking

Exclusion Criteria:

* Under 18 years
* Vulnerable population
Acute Stroke Thrombectomy: Does CT Perfusion Accurately Predict Infarct on MRI After Recanalization

The newest generation of stent---retrievers results in higher recanalization rates and faster recanalization time compared to older generation endovascular therapies for acute stroke. Advanced neuroimaging can potentially improve the assessment of infarct core and inform decision---making in patients being considered for endovascular therapy. Evaluation of infarct core may be performed with NECT, CTASI or CT perfusion. In the past, evaluation of CTP in predicting core infarct in acute stroke has been limited because recanalization status was lacking. In addition, final infarct size may be underestimated on NECT compared with MRI. These two limitations can now be addressed: the new generation of stent---retrievers allows accurate determination recanalization time; evaluating the test characteristics of CTP using 24 hour DWI---MRI as the reference standard can be readily performed.

We aim to prospectively investigate the sensitivity and specificity of whole---brain CTP in predicting 24 hour DWI---MRI infarct in patients with acute proximal anterior circulation occlusions successfully recanalized with endovascular treatment.


Eligibility Criteria:
Inclusion Criteria:

1. Admission NECT, CTA neck and COW or multi-phase CTA or CTP. Follow---up 24 hr DWI---MRI performed
2. Endovascular therapy performed for acute anterior circulation stroke as per clinical practice.
3. Patient with an angiographically documented ICA, M1 or M2 occlusion

Exclusion Criteria:

None
Video Consultation in CPAP for Patients With Obstructive Sleep Apnea

The objective of this study is to evaluate the effects of video consultation versus face-to-face consultation for patients with obstructive sleep apnea on patients' CPAP use (minutes/per night), self-efficacy, risk outcomes, outcome expectancies, experiences with technology and, patients' and nurses' satisfaction.

The objective of this study is to evaluate the effects of video consultation versus face-to-face consultation for patients with obstructive sleep apnea on patients' CPAP use (minutes/per night), self-efficacy, risk outcomes, outcome expectancies, experiences with technology and, patients' and nurses' satisfaction.

This study is a non-blinded randomized controlled trial with an intervention group (video consultations) and a usual care group (face-to-face consultations), with assessements after 1, 2, 3, 4, 12 and 24 weeks.

Patients were recruited from a large teaching hospital (Rijnstate, hospital), and included from January 2, 2019 until June 26, 2019.In total, 140 patients were randomized, (1:1 allocation).

Eligibility Criteria:
Inclusion Criteria:

* Older than 18 years
* Diagnosed with obstructive sleep apnea
* AHI \> 15
* Requiring CPAP treatment
* No history of CPAP treatment
* Having access to a tablet or smartphone
* Proficiency of the Dutch language

Exclusion Criteria:

* Psychiatric or cognitive disorder
Risk of Morbidity, Mortality and Long-term Monitoring of Antiretroviral Treatment in People Living With HIV

HIV infection is now a chronic disease in countries where antiretroviral treatments (ART) are largely available. Long-term follow-up is required to describe and understand the evolution of morbidities and complications as well as new treatments side effects.

The main objective of the cohort is to describe and study the evolution of HIV infection in ART-treated individuals.

The survival of people living with HIV (PLHIV) taking antiretroviral therapy (ART) is now close to what is reported in the general population in northern countries. However, PLHIV experience an increased risk of morbidities that the ANRS CO3 Aquitaine Cohort has largely contributed to describe in the last years. Among contributing factors to this excess of morbidity, immune suppression, immune activation, and exposition to cardiovascular and cancer risk factors as well as ageing represent possible intervention targets. Long-term follow-up is required to describe and understand the evolution of morbidities and complications as well as ART side effects.

Moreover, the global evaluation of health in PLHIV, including psychiatric, neurologic and social determinants and not only biomedical determinants represents one of the public health challenges of the next decade in the field of HIV infection.

The aim of the present study is to study the emerging morbidity occurring during the course of HIV infection in people treated with ART as well as to describe the tolerance and efficacy of new available ART regimens.

The follow-up of patients will be performed according to national guidelines. Demographic, clinical, biological and therapeutic data will be captured at each patient's hospital contact according to a standardized questionnaire.

All events occurring during the course of clinical management will be prospectively registered in the database according to the ICD 10th revision. A biobank will be collected from every consenting PLHIV at inclusion in the cohort and then every two years.

Eligibility Criteria:
Inclusion Criteria:

* Patients aged over 18 years old.
* Confirmed HIV infection
* Signed informed consent

Exclusion Criteria:

* HIV-2 infection
Fluciclovine-PET/CT for Bone Metastases From Prostate Adenocarcinoma

Determine diagnostic accuracy of Axumin-PET positive bone lesion by confirmatory bone biopsy.


Eligibility Criteria:
Inclusion Criteria:

1. Male
2. Be ≥ 18 years of age
3. Diagnosed with prostate cancer
4. Be willing and able to provide informed consent
5. Be informed of the investigational nature of this study

Exclusion Criteria:

1. Having a history of severe claustrophobia
2. Weight exceeding 400lbs
Efficacy and Safety Study of 4-Day ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT

The purpose of this study is to determine the efficacy and safety of combined ATG #antithymocyte globulin # regimen (5mg/kg divided from day -5 to day -2) for aGVHD(acute graft-versus-host disease ) prophylaxis in matched sibling donor peripheral blood stem cell transplantation (MSD-PBSCT).

Transplantation with G-CSF #Granulocyte colony stimulating factor #mobilized peripheral blood stem cell (PBSCT) has been a stable transplant setting with matched sibling donor transplantation. Unmanipulated haploidentical donor PBSCT (haplo-PBSCT) has been applied in patients with hematologic malignancies. In our previous cohort study, haplo-PBSCT was associated with lower incidence of severe acute GVHD and extensive chronic GVHD compared with matched sibling donor PBSCT (MSD-PBSCT). Haplo-PBSCT has the same GVHD prophylaxis regimen with MSD-PBSCT, except ATG. It suggested the potential advantage of ATG in prophylaxis of GVHD and improvement of long term quality of life of the transplant recipients, which motivate us to observe the efficacy of combined ATG regimen for GVHD prophylaxis in MSD-PBSCT.

Eligibility Criteria:
Inclusion Criteria:

* Patients were aged from 14 to 65 years;
* Patients were diagnosed of acute leukemia or MDS;
* There were indications of MSD-PBSCT for these patients;
* Patients without any uncontrolled infections or without severe pulmonary, renal, hepatic or cardiac diseases.

Exclusion Criteria:

* Patients with any uncontrolled infections or with severe pulmonary,renal, hepatic or cardiac diseases;
* AML patients with t (15;17).
Safety and Efficacy of PolyHeme(R) in Hemorrhagic Shock Following Traumatic Injuries Beginning in the Pre-Hospital Setting

This study is designed to assess the survival benefit of administering PolyHeme to severely injured trauma patients in hemorrhagic shock beginning in the prehospital setting, where blood is not available, and continuing throughout a 12-hour postinjury hospital setting.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients following trauma who have sustained blood loss and are in shock

Exclusion Criteria:

* Patients who have sustained unsurvivable injuries
* Patients who have severe head injury
* Pregnant females
* Patients found in cardiac arrest
* Patients who object to participation (e.g., religious grounds, wearing exclusion bracelet).